PEG-Conjugated K-252a for Reduced Systemic Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical agents like K-252a face challenges with poor solubility and rapid elimination, leading to ineffective therapeutic use due to systemic toxicity and side effects, particularly when administered topically.
Innovation Solution
Development of polymer conjugates, specifically with polyethylene glycol (PEG), to enhance pharmacokinetic and toxicologic properties, such as increased solubility and reduced systemic absorption, thereby minimizing side effects and improving bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If K-252a is administered topically, then therapeutic effect is achieved, but systemic toxicity and side effects occur due to poor solubility and rapid elimination
Solution Approach 1:
The patent employs polyethylene glycol (PEG) as an intermediary carrier molecule to conjugate with K-252a. This PEG conjugate acts as a mediator that improves the solubility and pharmacokinetic properties of K-252a, enabling effective topical delivery while reducing systemic absorption and toxicity. The PEG chain serves as a bridge between the drug molecule and the biological system, facilitating controlled delivery.
Solution Approach 2:
The patent modifies the chemical parameters of K-252a by conjugating it with PEG chains of varying molecular weights. This parameter change transforms the lipophilic K-252a into a more hydrophilic conjugate with improved solubility characteristics. The modification alters the molecular weight, hydrophilicity, and pharmacokinetic profile of the compound, enabling it to achieve therapeutic effects with reduced systemic toxicity.
2Reliability
If K-252a is used to inhibit kinase activity, then therapeutic effect is achieved, but selectivity is poor leading to off-target effects
Solution Approach 1:
The patent applies local quality modification by attaching PEG chains to specific positions on the K-252a molecule. This localized modification at the molecular level alters the drug's interaction properties with different kinase targets, potentially improving selectivity for TrkA while reducing off-target effects on other kinases. The PEG conjugation creates a locally modified structure that maintains kinase inhibitory activity while enhancing target specificity.
3Reliability
If PEG conjugation is used to improve solubility, then bioavailability increases, but molecular complexity increases
Solution Approach 1:
The patent creates a composite molecular structure by combining K-252a with PEG chains. This composite approach merges the pharmacologically active indolocarbazole core with the hydrophilic PEG polymer chain, resulting in a hybrid molecule that exhibits both the kinase inhibitory properties of K-252a and the solubility-enhancing characteristics of PEG. The composite structure effectively combines the benefits of both components.
Data Source
Figure 1a~1b
Figure 2
Figure 3
AI summary
The present invention relates to novel polymer conjugates of K-252a and derivatives thereof and to their use for the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of kinase-associated pathologies. In particular, the present invention relates to the prevention, alleviation and treatment of HMGB1-associated pathologies. In a particular aspect, the invention relates to the use of the novel polymer conjugates of K-252a and derivatives thereof in the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of neurological disorders, neuropathies and neurodegenerative disorders of the central and peripheral nervous system. In a further preferred aspect, the invention relates to the use of the polymer conjugates in the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of dermal pathologies, in particular dermal pathologies associated with an excessive keratinocyte proliferation, in particular psoriasis. In a still further aspect, the invention relates to the use of the polymer conjugates in the prevention, alleviation and treatment of NGF-related pain. More specifically, the present invention relates to a polymer conjugate of K-252a and derivatives thereof, wherein the polymer is polyethylene glycol or methoxy-polyethylene glycol formula (I).